Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Glenn S Tillotson

Glenn S Tillotson

Cempra Pharmaceuticals, USA

Title: The burden of antibiotic resistance

Biography

Biography: Glenn S Tillotson

Abstract

Antimicrobial resistance (AMR) is an escalating problem globally. The consequences of resistance may include increased morbidity and mortality. However the economic impact of this problem is poorly understood. In addition to enormous human cost of AMR there have been attempts to estimate the economic costs as well. These would be either direct healthcare costs such as increased length of hospital stays, loss of productivity or secondary social costs such as foregoing medical procedures or refraining from travel because of increased risk. In 2013, the CDC estimated that the direct costs of AMR were US $20 billion with additional productivity losses of US $35 billion. The CDC has also published a list of bacterial species in which antibiotic resistance has reached significant levels. The impact of antibiotic resistance in five species will be discussed namely; Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae. The global implications of antibiotic resistance will be put into perspective.